Overview

Cemiplimab and Cetuximab Prior Salvage Surgery in Patients With Recurrent Oral Cavity Squamous Cell Carcinoma (OCSCC).

Status:
RECRUITING
Trial end date:
2027-05-15
Target enrollment:
Participant gender:
Summary
To learn if giving cemiplimab and cetuximab before salvage surgery can help to control recurrent oral cavity squamous cell carcinoma.
Phase:
PHASE2
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborator:
Regeneron Pharmaceuticals
Treatments:
cemiplimab
Cetuximab